A limitation of PSMA PET/CT in response assessment is the persistence of PSMA expression in non-viable tumor cells, which can lead to false positive results, requiring complementary imaging or biomarkers for confirmation [51]. The gene discussed is FOLH1; the disease is neoplasm.